CRSP240920P52000
- 1.26
- 0.000.00%
CRISPR Therapeutics Newsroom
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Duan Yongping followed Buffett and sold some Apple! The investment giants made big moves in the second quarter.
As for Apple, Buffett, Duan Yongping, and Bridgewater are reducing their stakes, while Jinglin, Hillhouse, and the Norwegian Sovereign Fund are increasing theirs. In general, investment giants are still somewhat wary of tech giants.
Express News | CRISPR Therapeutics AG : Truist Securities Cuts Target Price to $100 From $120
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
On Aug 06, major Wall Street analysts update their ratings for $CRISPR Therapeutics(CRSP.US)$, with price targets ranging from $30 to $105.Barclays analyst Gena Wang maintains with a hold rating,
Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler
Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94